Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 25Carcinoma, Non-Small-Cell Lung 14Squamous Cell Carcinoma of Head and Neck 11Melanoma 10Breast Neoplasms 10Urinary Bladder Neoplasms 9Colorectal Neoplasms 9Lung Neoplasms 6Cholangiocarcinoma 6Carcinoma, Renal Cell 6Biliary Tract Neoplasms 6Adenocarcinoma Of Esophagus 6Ovarian Neoplasms 5Liver Neoplasms 5Diabetes Mellitus, Insulin-Dependent, 12 5Uterine Cervical Neoplasms 4Stomach Neoplasms 4Small Cell Lung Carcinoma 4Prostatic Neoplasms 4Pancreatic Neoplasms 4Mesothelioma, Malignant 4Head and Neck Neoplasms 4Neoplasm Metastasis 3Mesothelioma 3Kidney Neoplasms 3Fallopian Tube Neoplasms 3Endometrial Neoplasms 3Carcinoma, Transitional Cell 3Vulvar Neoplasms 2Vaginal Neoplasms 2

Interventions

Paclitaxel 2tremelimumab 1pegfilgrastim 1durvalumab 1Taxes 1Sunitinib 1Lapatinib 1Ifosfamide 1Darbepoetin alfa 1Cisplatin 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Dysgerminoma × tremelimumab × Clear all
NCT03158064 2026-01-28

Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
30 enrolled

Nonseminomatous germ cell tumor, Dysgerminoma, Neoplasms, Germ Cell and Embryonal, Germinoma, Seminoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡